Abstract 125P
Background
Esophageal cancer (EC) takes, all over the world, 9th place in the structure of new incidents of malignant tumors, amounting to 572034 registered cases and 6th place in the structure of mortality rate, taking 508585 lives annually. According to statistical data, EC develops much more often in men than in women (70% of new cases have developed in men), and people over 70 make up about 40% of the total number of cases, with a peak incidence occurring at the age of 50-60 years. However, these indicators vary by geographic region. So, for example, the highest incidence is found in East Asia, eastern and southern Africa (8.1-23.6‱), while the lowest rate belongs to central America. The aim of the research was to study the dynamics of changes in the incidence trends in the Republic of Uzbekistan over the past 20 years.
Methods
A meta-analysis of the detection of mortality of esophageal cancer (EC) for all patients with the verified diagnosis was performed. For the period from 2000 - 2019, 18129 patients were identified in the Uzbekistan and the average incidence of EC was 2.8 per 100 thousand of the population. Of these 8283 (45.7%) were treated at the clinic of NCC, in particular, 1174 (14.2%) patients were operated.
Results
The analysis revealed that in 2000, in 0,4% and 18,2% of cases, patients had I - II stage disease, in 64,5% of cases – III, and in 18,2% of cases – IV clinical stage, in 2009, 0,5% and 22,8% of cases, patients had I - II stage disease, in 54,4% of cases – III, and in 16,4% of cases - IV clinical stage, and in 2019, 3,3% and 33,7% of cases patients had I – II stage disease, in 44,5% of cases - III, and in 12,5% of cases - IV clinical stage.
Conclusions
A relative decrease in the mortality rate over the study period was also revealed: from 2.7% in 2000 to 1.8% in 2019. There has been a decrease in the mortality trend - 2000, 2009 and 2019, 2.2, 1.7 and 1.1, respectively. At the same time, 5-year survival was relatively stable and varied in the range of 12.1% - 27.3%. The largest number of patients was identified in the clinical stage III of the disease and ranged from 42.2 to 67%, respectively.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Republican Specialized Oncology and Radiology Research - Practice Medical Center (National Cancer Center).
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
14P - BRCA mutation and clinical outcomes in breast cancer focusing on survivals and failure patterns: A long-term follow-up study of Koreans
Presenter: Hakyoung Kim
Session: e-Poster Display Session
15P - Designing of multimodal targeted tumor-seeking nanomedicine for triple-therapeutic effect
Presenter: Vellingiri Yasothamani
Session: e-Poster Display Session
16P - Topical henna cream in prevention of radiation-induced dermatitis in breast cancer: A randomized double-blind clinical trial
Presenter: Mansour Lesan
Session: e-Poster Display Session
17P - Comparison of dose distribution in the postoperative breast cancer patients irradiated with the technique of deep inspiratory breath hold and dynamic techniques
Presenter: Ewa Telka
Session: e-Poster Display Session
18P - A prospective randomized study comparing cosmetic outcome of sequential electron boost versus simultaneous integrated boost with IMRT to lumpectomy cavity during adjuvant radiotherapy to breast following BCS in carcinoma breast in Indian patients
Presenter: Sravya Bommera
Session: e-Poster Display Session
19P - Musculoskeletal pain and health-related quality of life among breast cancer patients
Presenter: Aslin Valiyagath
Session: e-Poster Display Session
20P - Molecular parallelisms and divergences between human and canine cancers
Presenter: Sadaf Ambreen
Session: e-Poster Display Session
21P - Neoadjuvant trastuzumab and pertuzumab in real-world data population in two medical institutions in Portugal
Presenter: Isabel Gomes Fernandes
Session: e-Poster Display Session
22P - Correlation of muscle strength and quality of life in Indonesian breast cancer patients who underwent chemotherapy
Presenter: Devina Halim
Session: e-Poster Display Session
23P - Oncotype DX RS correlation with clinicopathologic risk factors and chemotherapy: Follow up based on TAILORx study
Presenter: Faroug Ali
Session: e-Poster Display Session